Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/11100
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAkbarova D.S., Kakharova N.M., Musayeva L.J., Komolova F.J.-
dc.date.accessioned2024-05-21T10:44:13Z-
dc.date.available2024-05-21T10:44:13Z-
dc.date.issued2024-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/11100-
dc.description.abstractCommunity-acquired pneumonia is an urgent problem that requires effective treatment. For effective treatment of pneumonia, it is necessary to choose the right fluoroquinolone, taking into account the sensitivity of the pathogen and the pharmacokinetic characteristics of the drug. In this case, it is necessary to take into account the pronounced side effects and limitations of the use of these drugs. An important step is to determine the dosage and duration of treatment. The effectiveness and safety of treatment of pneumonia with fluoroquinolones is manifested in clinical and laboratory parameters. This article reviews a comparative study of moxifloxacin with levofloxacin in the treatment of community-acquired pneumonia, and compares the effectiveness and safety of these drugs.en_US
dc.language.isoen_USen_US
dc.publisherJOURNAL OF MEDICINE AND PHARMACYen_US
dc.relation.ispartofseriesUDK;615.038-
dc.subjectcommunity-acquired pneumonia, fluoroquinolones, moxifloxacin, levofloxacin.en_US
dc.titleCOMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF МOXIFLOXACIN AND LEVOFLOXACIN THERAPY IN THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA.en_US
dc.typeArticleen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
5.pdfCOMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF МOXIFLOXACIN AND LEVOFLOXACIN THERAPY IN THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA.516.2 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.